Science and technology company Battelle disclosed on Monday that Dr Wayne A I Frederick, current president of Howard University and the Charles R Drew Professor of Surgery, has been elected to the Battelle board of directors.
Dr Frederick will initially serve in an advisory role and will become a full voting member on the company's board in 2022.
Following post-doctoral research and surgical oncology fellowships at the University of Texas MD Anderson Cancer Center, Dr Frederick began his academic career as associate director of the cancer center at the University of Connecticut. He was appointed the seventeenth president of Howard University in 2014 and has been responsible for advancing the university's commitment to student opportunity, academic innovation, public service, and fiscal stability. He previously served as provost and chief academic officer.
Currently, Dr Frederick serves on the board of directors for the Federal Reserve Bank of Richmond and Humana Inc.
Headquartered in Columbus, Ohio and founded in 1929, Battelle conducts research and development, designs and manufactures products, and delivers critical services for government and commercial customers. Battelle also supports science, technology, engineering and mathematics (STEM) education.
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
Seegene launches STAgora infectious disease analytics platform
Alvotech and Advanz Pharma sign European deal for Cimzia biosimilar
Amgen's Phase 3 bemarituzumab plus chemotherapy clinical trial meets primary endpoint
TuHURA Biosciences acquires Kineta
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Mabwell and Qilu Pharmaceutical enter licence agreement for Albipagrastim alfa for Injection
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies